A Phase 1, Double-blind, Randomized Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult Subjects
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Lumicitabine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 14 Sep 2016 Status changed from recruiting to completed.
- 08 Jul 2016 New trial record